Coverage at a glance
| Indication | Coverage |
|---|---|
| Type 2 diabetes | Covered with prior authorization |
Plan type: Commercial non-Medicare. Each indication below lists the BMI and clinical thresholds, the prior-authorization documentation, and the published policy it comes from.
Coverage by indication
What the prior authorization needs:
- Prior authorization required under UnitedHealthcare clinical program 2026 P 1332-8, effective July 1, 2026.
- Medical records confirming type 2 diabetes, evidenced by one of: A1C greater than or equal to 6.5 percent, fasting plasma glucose greater than or equal to 126 mg/dL, 2-hour plasma glucose greater than or equal to 200 mg/dL on an oral glucose tolerance test, or random plasma glucose greater than or equal to 200 mg/dL with classic symptoms of hyperglycemia.
- For patients diagnosed more than 2 years ago, chart notes confirming the type 2 diabetes diagnosis are accepted.
- Authorization is issued for 12 months.
- No step therapy required. The April 2025 revision removed the note that step therapy may apply.
- Quantity limit (QL) applies per the 2026 commercial Prescription Drug List (effective January 1, 2026), where Ozempic also carries the 'E' designation, meaning it may be excluded from coverage or subject to prior authorization in Connecticut, New Jersey and New York. PDL source: https://www.uhcprovider.com/content/dam/provider/docs/public/resources/pharmacy/commercial-pdl-jan-2026.pdf
- Not FDA-approved for weight loss. Medications used for weight loss are typically excluded from benefit coverage.
Policy 2026 P 1332-8. Source: UnitedHealthcare Pharmacy Clinical Pharmacy Programs. Prior Authorization/Notification: Diabetes Medications, GLP-1 & Dual GIP/GLP-1 Receptor Agonists. Program Number 2026 P 1332-8. payer_policy. Verified August 27, 2026.
Recent change: UnitedHealthcare's April 2025 revision to this GLP-1 program removed the prior note that step therapy may apply, so the current 2026 program does not require a metformin trial before approving Ozempic for type 2 diabetes. The program was reaffirmed at annual review with an effective date of July 1, 2026.
What to do next
If you qualify under one of the covered indications above, prior authorization is the path. Match the documentation in the requirements list then have your prescriber submit it. Plans that approve reassess at renewal, so know your long-term maintenance dose before you start.
- Browse the prior-authorization letter library for a template that matches your plan and indication.
- Read the full coverage picture, denial reasons, and the four appeal pathways at GLP-1 insurance coverage.
- If the prior-authorization request is denied, the appeal letter library has templates by denial reason, covering peer-to-peer review, Level 1 and Level 2 internal appeal, and external review.
- If your plan does not cover the indication you need, compare cash prices in the cost guide or check whether a clinical trial near you fits. Neither one goes through your insurer. Clinical trials cost nothing and many pay you for your time. Some participants get a placebo, decided at random.
What it costs without insurance
The programs below bill you directly. Prices checked every Monday.
Frequently asked questions
Does UnitedHealthcare cover Ozempic?
UnitedHealthcare, through OptumRx, covers Ozempic for adults with type 2 diabetes on its 2026 commercial drug list, with prior authorization and a quantity limit. Approval requires records confirming a type 2 diabetes diagnosis, shown by an A1C of 6.5 percent or higher or another qualifying lab value, or chart notes for patients diagnosed more than two years ago. The 2026 policy does not require step therapy, and an approval lasts 12 months. UnitedHealthcare does not cover Ozempic for weight loss, which is off-label and excluded from most plans. That indication belongs to Wegovy, the same semaglutide at a higher dose. This reflects the published policy verified August 2026.
What does UnitedHealthcare require to approve Ozempic?
For type 2 diabetes: Prior authorization is required, with the documentation listed in the requirements above.
Coverage for other payers
See the full payer coverage index for every plan we have sourced.
How we built this page
Each page is built from a published payer policy document, government statute, or independent formulary analysis (KFF). Every indication row carries the source URL and the date we verified it. Where a payer's policy PDF was confirmed at its public URL but served as an unreadable binary, the policy number and coverage framework were cross-checked against secondary sources; those rows are marked lower confidence. Commercial coverage often depends on whether an employer elected the weight-management benefit. Those rows say varies by plan rather than a flat yes.
This is reference information, not medical or legal advice, and not a guarantee of coverage. GLP-1 coverage policies change often. Always confirm the current policy with your insurer using the number on your card before you rely on this page. If your experience differs from what is shown here, email hello@glpchart.com with the details and we will re-verify.
